Chronic myelomonocytic leukaemia

A concise clinical and pathophysiological review

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Chronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell disorder with myelodysplastic and myeloproliferative overlap features, and an inherent tendency to transform to acute myeloid leukaemia. Approximately 30% of patients present with clonal cytogenetic abnormalities, while almost 90% have molecular aberrations involving epigenetic regulation, the spliceosome component machinery, tumour suppressor genes and transcription factors/regulators. Numerous prognostic models exist for CMML, with more recent models incorporating prognostic mutations, such as those involving ASXL1. Other variables that seem to consistently affect outcomes include the degree of leucocytosis/monocytosis, anaemia and thrombocytopenia. Allogeneic stem cell transplant remains the only curative option for CMML, while hypomethylating agents can be used for transplant-ineligible patients or those without suitable stem cell sources. Targeting biological pathways activated in CMML offers potential hope for more effective and less toxic therapies.

Original languageEnglish (US)
Pages (from-to)273-286
Number of pages14
JournalBritish Journal of Haematology
Volume165
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Leukemia, Myelomonocytic, Chronic
Stem Cells
Spliceosomes
Transplants
Poisons
Leukocytosis
Hematopoietic Stem Cells
Tumor Suppressor Genes
Acute Myeloid Leukemia
Epigenomics
Chromosome Aberrations
Thrombocytopenia
Anemia
Transcription Factors
Mutation

Keywords

  • Allogeneic stem cell transplant
  • ASXL1
  • Chronic myelomonocytic leukaemia
  • Hypomethylating agents
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Chronic myelomonocytic leukaemia : A concise clinical and pathophysiological review. / Patnaik, Mrinal M; Parikh, Sameer A; Hanson, Curtis A.; Tefferi, Ayalew.

In: British Journal of Haematology, Vol. 165, No. 3, 2014, p. 273-286.

Research output: Contribution to journalArticle

@article{85d040b092b346f49684250963411295,
title = "Chronic myelomonocytic leukaemia: A concise clinical and pathophysiological review",
abstract = "Chronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell disorder with myelodysplastic and myeloproliferative overlap features, and an inherent tendency to transform to acute myeloid leukaemia. Approximately 30{\%} of patients present with clonal cytogenetic abnormalities, while almost 90{\%} have molecular aberrations involving epigenetic regulation, the spliceosome component machinery, tumour suppressor genes and transcription factors/regulators. Numerous prognostic models exist for CMML, with more recent models incorporating prognostic mutations, such as those involving ASXL1. Other variables that seem to consistently affect outcomes include the degree of leucocytosis/monocytosis, anaemia and thrombocytopenia. Allogeneic stem cell transplant remains the only curative option for CMML, while hypomethylating agents can be used for transplant-ineligible patients or those without suitable stem cell sources. Targeting biological pathways activated in CMML offers potential hope for more effective and less toxic therapies.",
keywords = "Allogeneic stem cell transplant, ASXL1, Chronic myelomonocytic leukaemia, Hypomethylating agents, Prognosis",
author = "Patnaik, {Mrinal M} and Parikh, {Sameer A} and Hanson, {Curtis A.} and Ayalew Tefferi",
year = "2014",
doi = "10.1111/bjh.12756",
language = "English (US)",
volume = "165",
pages = "273--286",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Chronic myelomonocytic leukaemia

T2 - A concise clinical and pathophysiological review

AU - Patnaik, Mrinal M

AU - Parikh, Sameer A

AU - Hanson, Curtis A.

AU - Tefferi, Ayalew

PY - 2014

Y1 - 2014

N2 - Chronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell disorder with myelodysplastic and myeloproliferative overlap features, and an inherent tendency to transform to acute myeloid leukaemia. Approximately 30% of patients present with clonal cytogenetic abnormalities, while almost 90% have molecular aberrations involving epigenetic regulation, the spliceosome component machinery, tumour suppressor genes and transcription factors/regulators. Numerous prognostic models exist for CMML, with more recent models incorporating prognostic mutations, such as those involving ASXL1. Other variables that seem to consistently affect outcomes include the degree of leucocytosis/monocytosis, anaemia and thrombocytopenia. Allogeneic stem cell transplant remains the only curative option for CMML, while hypomethylating agents can be used for transplant-ineligible patients or those without suitable stem cell sources. Targeting biological pathways activated in CMML offers potential hope for more effective and less toxic therapies.

AB - Chronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell disorder with myelodysplastic and myeloproliferative overlap features, and an inherent tendency to transform to acute myeloid leukaemia. Approximately 30% of patients present with clonal cytogenetic abnormalities, while almost 90% have molecular aberrations involving epigenetic regulation, the spliceosome component machinery, tumour suppressor genes and transcription factors/regulators. Numerous prognostic models exist for CMML, with more recent models incorporating prognostic mutations, such as those involving ASXL1. Other variables that seem to consistently affect outcomes include the degree of leucocytosis/monocytosis, anaemia and thrombocytopenia. Allogeneic stem cell transplant remains the only curative option for CMML, while hypomethylating agents can be used for transplant-ineligible patients or those without suitable stem cell sources. Targeting biological pathways activated in CMML offers potential hope for more effective and less toxic therapies.

KW - Allogeneic stem cell transplant

KW - ASXL1

KW - Chronic myelomonocytic leukaemia

KW - Hypomethylating agents

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84898488422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898488422&partnerID=8YFLogxK

U2 - 10.1111/bjh.12756

DO - 10.1111/bjh.12756

M3 - Article

VL - 165

SP - 273

EP - 286

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -